Citeline_RD2025-2025医药研发年度回顾-英文版_66页_29mb

Summary: 2025 Pharma R&D Annual Review (Citeline)

Introduction

The 2025 Citeline Pharma R&D Annual Review explores trends in pharmaceutical pipeline development, drawing parallels with the fashion industry’s evolution. The report highlights a stable yet adapting pharma sector, characterized by a growing dominance of biotechnology-based drugs and shifting therapeutic priorities.

Overall Pipeline Trends

• The pipeline saw a 4.6% increase in 2025, with a notable concentration of biotech drugs accounting for 49.8% of the pipeline, signaling a potential shift toward biologics over traditional small molecules.
• Oncology remains central, with 39.7% of all drugs targeting cancer. Immuno-oncology therapies saw a 4.9% growth and outpace traditional cancer treatments, supported by key players like Roche and Novartis, which led pipeline size rankings.

Regional Variations

• North America/China: Both regions drive R&D, with China showing explosive growth in novel drug development. U.S.-based firms maintain a larger pipeline but face slowing growth.
• Europe: Countries like the UK, Ireland, and Germany exhibit strong but varied R&D activity. Ireland leads per capita, while France and Germany face growth moderation.
• Asia-Pacific: China dominates, followed by Japan, India, and South Korea. India shows accelerating drug development, though still lagging behind China.
• Rest of World: Emerging nations like Brazil contribute minimally.

Mechanisms and Drug Types

• Biotech Dominance: Gene therapies (2,178 pipeline drugs) and cell therapies (2,719 pipeline drugs) are advancing rapidly. CAR-T therapies and CRISPR-based approaches led gains in 2025.
• Immunotherapy: Immuno-oncology therapies clocked 4,125 pipeline drugs, with antibodies—especially monoclonal antibodies—remaining pivotal. Bispecific antibodies saw significant growth.
• Drug Delivery: Injectable drugs still dominate (49% of pipeline), though oral routes show slight recovery.

Forecast and Outlook

• The industry faces geopolitical risks associated with a new US administration and potential trade tensions with China, which influence R&D investments but do not dim optimism.
• Funding for biopharma increased in 2024, with 2,341 M&A deals and continued investment in AI-powered drug discovery, which is revolutionizing R&D cycles.

Key Takeaway

Ian Lloyd, Citeline’s Senior Director, emphasizes that the pharma industry needs continued innovation, particularly in biologics and targeted therapies, to meet evolving therapeutic challenges. The “fashion” metaphor applied here reflects the cyclical nature of pipeline trends but underscores the slower, science-driven adaptations of pharma R&D compared to the fashion world.

Table: Growth in Key Pipeline Categories (2025 vs. Historical)

Throughout the report, trends reflect a convergence toward targeted biologics and immunotherapies, while geopolitical and economic uncertainties add cautious optimism to the forecast.